A number of firms have modified their ratings and price targets on shares of Design Therapeutics (NASDAQ: DSGN) recently:
- 5/12/2026 – Design Therapeutics is now covered by Cantor Fitzgerald. They set an “overweight” rating on the stock.
- 5/10/2026 – Design Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
- 5/4/2026 – Design Therapeutics had its price target raised by Oppenheimer Holdings, Inc. from $18.00 to $21.00. They now have an “outperform” rating on the stock.
- 5/2/2026 – Design Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
- 4/29/2026 – Design Therapeutics had its “overweight” rating reaffirmed by Piper Sandler. They now have a $20.00 price target on the stock.
- 4/20/2026 – Design Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
- 3/16/2026 – Design Therapeutics is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $15.00 price target on the stock.
Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders.
See Also
- Five stocks we like better than Design Therapeutics
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
- 3 AI Data Center Stocks Worth Watching for Capital Rotation
- McDonald’s Is the Cheapest It’s Been in Years—Does That Make It a Buy?
- Karman: Defense Darling’s Outlook Strengthens After 40% Drop
Receive News & Ratings for Design Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Design Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.
